Cargando…
Allelic Frequency of p53 Gene Codon 72 Polymorphism in Urologic Cancers
Alterations in the p53 tumor suppressor gene appear to be important in the development of many human tumors. The wild‐type p53 gene has a polymorphism at codon 72 that presents the arginine (CGC) or proline (CCC) genotype, which recently has been reported to be associated with genetically determined...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
1995
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920911/ https://www.ncbi.nlm.nih.gov/pubmed/7559095 http://dx.doi.org/10.1111/j.1349-7006.1995.tb02461.x |
_version_ | 1783317903310848000 |
---|---|
author | Wu, Wen‐Jeng Kakehi, Yoshiyuki Habuchi, Tomonori Kinoshita, Hidefumi Ogawa, Osamu Terachi, Toshiro Huang, Chun‐Hsiung Chiang, Chin‐Pei Yoshida, Osamu |
author_facet | Wu, Wen‐Jeng Kakehi, Yoshiyuki Habuchi, Tomonori Kinoshita, Hidefumi Ogawa, Osamu Terachi, Toshiro Huang, Chun‐Hsiung Chiang, Chin‐Pei Yoshida, Osamu |
author_sort | Wu, Wen‐Jeng |
collection | PubMed |
description | Alterations in the p53 tumor suppressor gene appear to be important in the development of many human tumors. The wild‐type p53 gene has a polymorphism at codon 72 that presents the arginine (CGC) or proline (CCC) genotype, which recently has been reported to be associated with genetically determined susceptibility to smoking‐related lung cancers. To determine whether this p53 genotype influences individual risk of urologic cancer and/or its progression, we used polymerase chain reaction‐restriction fragment length polymorphism (PCR‐RFLP) analysis to assay the allelic frequencies of this polymorphism in 85 renal cell carcinoma patients, 151 urothelial cancer patients, 33 testicular cancer patients, 28 prostatic cancer patients and 56 patients without neoplastic disease. The allelic distributions of the three genotypes (Arg/Arg, Arg/Pro, Pro/Pro) in patients with renal cell carcinoma (29.4%, 55.3%, 15.3%), urothelial cancers (45.7%, 39.7%, 14.6%), testicular cancer (45.4%, 48.5%, 6.1%) or prostate cancer (42,9%, 50.0%, 7.1%) did not differ significantly from those in the normal controls. However, Pro/Pro genotype in renal cell carcinoma and urothelial cancer (smoking‐related cancers) was more frequent than that in prostate cancer and testicular cancer (smoking‐unrelated cancers) with borderline significance (P=0.0881). There was no particular correlation between frequency of the three genotypes and grade or stage of each type of tumor. The association of genetic predisposition to urologic cancers with p53 gene codon 72 polymorphism is not so clear as the previous study of Japanese lung cancer patients, but this polymorphism may play some role in urothelial cancers and renal cell carcinoma, in which smoking is an epidemiological risk factor. |
format | Online Article Text |
id | pubmed-5920911 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1995 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-59209112018-05-11 Allelic Frequency of p53 Gene Codon 72 Polymorphism in Urologic Cancers Wu, Wen‐Jeng Kakehi, Yoshiyuki Habuchi, Tomonori Kinoshita, Hidefumi Ogawa, Osamu Terachi, Toshiro Huang, Chun‐Hsiung Chiang, Chin‐Pei Yoshida, Osamu Jpn J Cancer Res Article Alterations in the p53 tumor suppressor gene appear to be important in the development of many human tumors. The wild‐type p53 gene has a polymorphism at codon 72 that presents the arginine (CGC) or proline (CCC) genotype, which recently has been reported to be associated with genetically determined susceptibility to smoking‐related lung cancers. To determine whether this p53 genotype influences individual risk of urologic cancer and/or its progression, we used polymerase chain reaction‐restriction fragment length polymorphism (PCR‐RFLP) analysis to assay the allelic frequencies of this polymorphism in 85 renal cell carcinoma patients, 151 urothelial cancer patients, 33 testicular cancer patients, 28 prostatic cancer patients and 56 patients without neoplastic disease. The allelic distributions of the three genotypes (Arg/Arg, Arg/Pro, Pro/Pro) in patients with renal cell carcinoma (29.4%, 55.3%, 15.3%), urothelial cancers (45.7%, 39.7%, 14.6%), testicular cancer (45.4%, 48.5%, 6.1%) or prostate cancer (42,9%, 50.0%, 7.1%) did not differ significantly from those in the normal controls. However, Pro/Pro genotype in renal cell carcinoma and urothelial cancer (smoking‐related cancers) was more frequent than that in prostate cancer and testicular cancer (smoking‐unrelated cancers) with borderline significance (P=0.0881). There was no particular correlation between frequency of the three genotypes and grade or stage of each type of tumor. The association of genetic predisposition to urologic cancers with p53 gene codon 72 polymorphism is not so clear as the previous study of Japanese lung cancer patients, but this polymorphism may play some role in urothelial cancers and renal cell carcinoma, in which smoking is an epidemiological risk factor. Blackwell Publishing Ltd 1995-08 /pmc/articles/PMC5920911/ /pubmed/7559095 http://dx.doi.org/10.1111/j.1349-7006.1995.tb02461.x Text en |
spellingShingle | Article Wu, Wen‐Jeng Kakehi, Yoshiyuki Habuchi, Tomonori Kinoshita, Hidefumi Ogawa, Osamu Terachi, Toshiro Huang, Chun‐Hsiung Chiang, Chin‐Pei Yoshida, Osamu Allelic Frequency of p53 Gene Codon 72 Polymorphism in Urologic Cancers |
title | Allelic Frequency of p53 Gene Codon 72 Polymorphism in Urologic Cancers |
title_full | Allelic Frequency of p53 Gene Codon 72 Polymorphism in Urologic Cancers |
title_fullStr | Allelic Frequency of p53 Gene Codon 72 Polymorphism in Urologic Cancers |
title_full_unstemmed | Allelic Frequency of p53 Gene Codon 72 Polymorphism in Urologic Cancers |
title_short | Allelic Frequency of p53 Gene Codon 72 Polymorphism in Urologic Cancers |
title_sort | allelic frequency of p53 gene codon 72 polymorphism in urologic cancers |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920911/ https://www.ncbi.nlm.nih.gov/pubmed/7559095 http://dx.doi.org/10.1111/j.1349-7006.1995.tb02461.x |
work_keys_str_mv | AT wuwenjeng allelicfrequencyofp53genecodon72polymorphisminurologiccancers AT kakehiyoshiyuki allelicfrequencyofp53genecodon72polymorphisminurologiccancers AT habuchitomonori allelicfrequencyofp53genecodon72polymorphisminurologiccancers AT kinoshitahidefumi allelicfrequencyofp53genecodon72polymorphisminurologiccancers AT ogawaosamu allelicfrequencyofp53genecodon72polymorphisminurologiccancers AT terachitoshiro allelicfrequencyofp53genecodon72polymorphisminurologiccancers AT huangchunhsiung allelicfrequencyofp53genecodon72polymorphisminurologiccancers AT chiangchinpei allelicfrequencyofp53genecodon72polymorphisminurologiccancers AT yoshidaosamu allelicfrequencyofp53genecodon72polymorphisminurologiccancers |